December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

43.24 +0.84 (+1.98%)
Official Closing Price Updated: 4:10 PM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
News headline image
Teva Pharmaceutical Industries Targets Up to $7 Billion in Innovative Drug Revenue by 2030 ↗
Teva Pharmaceutical Industries (NYSE:TEVA) outlined plans to grow its innovative medicines business and advance a pipeline spanning neuroscience, immunology and cancer treatments at its first R&D Day.... 
Via MarketBeat
News headline image
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now? ↗
Teva's three branded therapies of Austedo, Ajovy, and Uzedy brought in $1.1 billion in third-quarter revenue. 
Via The Motley Fool
Teva Pharmaceutical (NYSE:TEVA) Sets Up for Breakout With 10/10 Technical Strength ↗
Via Chartmill
News headline image
What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call ↗
Teva Pharmaceutical Industries (NYSE:TEVA) reported third-quarter 2026 revenue of approximately $4.4 billion, down 2% from a year earlier, as growth in its innovative medicines portfolio was offset by... 
Via MarketBeat
Topics Earnings
Teva Pharmaceutical (NYSE:TEVA) Nears Breakout With Perfect Technical Rating and Bull Flag Setup ↗
Via Chartmill
News headline image
Teva (TEVA) Q3 2026 Earnings Call Transcript ↗
Innovative drugs offset generic declines as Teva raises full-year guidance. 
Via The Motley Fool
Topics Earnings
News headline image
Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years? ↗
Teva's pivot from generics to branded drugs has succeeded, but keep an eye out for this potential headwind. 
Via The Motley Fool
News headline image
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Where Will Neurocrine Biosciences Be in 5 Years? ↗
Neurocrine's expanding drug portfolio could drive substantial growth through 2031. 
Via The Motley Fool
News headline image
UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host R&D Day on Wednesday, November 11 in New York City
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA ↗
Teva Pharmaceutical Industries (NYSE:TEVA) said the U.S. Food and Drug Administration has approved WELTRUZA, a once-monthly subcutaneous long-acting injectable formulation of olanzapine for... 
Via MarketBeat
News headline image
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround ↗
Built on substance, not hype, Teva's mega rally is just getting started. 
Via The Motley Fool
News headline image
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Releases Q3 2026 Aide Memoire
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings ↗
Teva Pharmaceutical Industries (NYSE:TEVA) is planning for greater financial flexibility after receiving investment-grade ratings from all three major credit rating agencies, President and CEO Richard... 
Via MarketBeat
Topics Bankruptcy
News headline image
Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline ↗
Teva Pharmaceutical Industries (NYSE:TEVA) Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a generics manufacturer toward a biopharmaceutical company... 
Via MarketBeat
News headline image
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.